Vaccination Recommendations for Immunocompromised Patients with CVID

General Principles

The American Academy of Allergy, Asthma, and Immunology recommends that patients with Common Variable Immunodeficiency (CVID) avoid all live vaccines while inactivated vaccines can be administered with caution, though they may have limited efficacy due to impaired antibody production 1, 2
Patients with CVID have major antibody deficiencies and typically receive immunoglobulin replacement therapy, which affects vaccination strategies 3
Inactivated vaccines are generally safe in CVID patients but may have limited efficacy due to impaired antibody production and the presence of passive antibodies from immunoglobulin therapy 3, 4
Live vaccines should be avoided in CVID patients due to potential risks of vaccine-related disease, even though the actual occurrence of complications is rare 1, 5

Inactivated vaccines other than influenza vaccine (IIV) are not routinely administered to CVID patients during immunoglobulin therapy as they have limited benefit 3, 6
Influenza vaccine (IIV) can be administered to CVID patients with some residual antibody production, as it may provide some protection through T-cell-mediated responses even when on immunoglobulin therapy 3, 6
Live oral poliovirus vaccine (OPV) should not be administered to CVID patients due to documented risk of vaccine-associated paralytic poliomyelitis (VAPP) 1, 3
Other live vaccines to avoid in CVID patients include: measles-mumps-rubella (MMR), varicella, yellow fever, live attenuated influenza, and live bacterial vaccines (e.g., typhoid Ty21a) 1, 2, 5

Household members of CVID patients should receive all age-appropriate inactivated vaccines to create a "circle of protection" around the immunocompromised patient, as recommended by the Centers for Disease Control and Prevention 8
Annual influenza vaccination is strongly recommended for household members of CVID patients, according to the Advisory Committee on Immunization Practices 8

CVID patients often have variable T-cell function in addition to B-cell defects, which may further impact vaccine safety and efficacy 1, 5
Patients receiving immunoglobulin replacement therapy already have passive immunity against many pathogens, making vaccination less beneficial, as noted by the Infectious Diseases Society of America 3
The response to vaccines in CVID patients may correlate with the clinical severity of their immunodeficiency 3, 4